SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 137 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,664 | -89.4% | 69,463 | -76.9% | 0.00% | – |
| Q2 2023 | $391,255 | -29.6% | 300,965 | -4.6% | 0.00% | – |
| Q1 2023 | $555,494 | -47.5% | 315,622 | -6.3% | 0.00% | – |
| Q4 2022 | $1,057,144 | -69.0% | 336,670 | -51.7% | 0.00% | – |
| Q3 2022 | $3,414,000 | +31.5% | 696,797 | +11.1% | 0.00% | – |
| Q2 2022 | $2,596,000 | -34.4% | 626,963 | -7.9% | 0.00% | – |
| Q1 2022 | $3,957,000 | -62.6% | 681,038 | -51.7% | 0.00% | – |
| Q4 2021 | $10,580,000 | +54.7% | 1,410,516 | +85.9% | 0.00% | – |
| Q3 2021 | $6,838,000 | -25.2% | 758,878 | -0.6% | 0.00% | -100.0% |
| Q2 2021 | $9,141,000 | -3.5% | 763,639 | +1.0% | 0.00% | 0.0% |
| Q1 2021 | $9,470,000 | -73.2% | 755,710 | -66.7% | 0.00% | -66.7% |
| Q4 2020 | $35,400,000 | +180.0% | 2,268,498 | +69.6% | 0.00% | 0.0% |
| Q3 2020 | $12,644,000 | +13.8% | 1,337,948 | +7.9% | 0.00% | 0.0% |
| Q2 2020 | $11,109,000 | +72.5% | 1,239,869 | +22.6% | 0.00% | +50.0% |
| Q1 2020 | $6,441,000 | -50.0% | 1,011,206 | -34.3% | 0.00% | -50.0% |
| Q4 2019 | $12,878,000 | -26.1% | 1,538,600 | -20.1% | 0.00% | -33.3% |
| Q3 2019 | $17,427,000 | -72.6% | 1,925,570 | -67.5% | 0.01% | -25.0% |
| Q2 2019 | $63,717,000 | +224.1% | 5,916,033 | +187.0% | 0.01% | -11.1% |
| Q1 2019 | $19,662,000 | -11.3% | 2,061,036 | +6.8% | 0.01% | 0.0% |
| Q4 2018 | $22,159,000 | -41.5% | 1,930,231 | -13.7% | 0.01% | -25.0% |
| Q3 2018 | $37,894,000 | +49.9% | 2,235,598 | +25.6% | 0.01% | +50.0% |
| Q2 2018 | $25,281,000 | +39.5% | 1,780,373 | +86.6% | 0.01% | +14.3% |
| Q1 2018 | $18,125,000 | -22.0% | 953,952 | -32.7% | 0.01% | -22.2% |
| Q4 2017 | $23,246,000 | +59.1% | 1,417,430 | +45.5% | 0.01% | +50.0% |
| Q3 2017 | $14,614,000 | +74.9% | 974,233 | +2.6% | 0.01% | +50.0% |
| Q2 2017 | $8,357,000 | +228.1% | 949,634 | +93.9% | 0.00% | +300.0% |
| Q1 2017 | $2,547,000 | +103.6% | 489,689 | +19.4% | 0.00% | – |
| Q4 2016 | $1,251,000 | +44.0% | 410,194 | +118.8% | 0.00% | – |
| Q3 2016 | $869,000 | -53.8% | 187,488 | -42.3% | 0.00% | – |
| Q2 2016 | $1,881,000 | -25.7% | 324,818 | -22.4% | 0.00% | -100.0% |
| Q1 2016 | $2,531,000 | -81.3% | 418,330 | -71.7% | 0.00% | -85.7% |
| Q4 2015 | $13,500,000 | +30.7% | 1,478,600 | -19.3% | 0.01% | +40.0% |
| Q3 2015 | $10,331,000 | -51.7% | 1,831,752 | -5.1% | 0.01% | -44.4% |
| Q2 2015 | $21,410,000 | -32.5% | 1,930,598 | -4.6% | 0.01% | -35.7% |
| Q1 2015 | $31,725,000 | -6.7% | 2,023,261 | -9.5% | 0.01% | 0.0% |
| Q4 2014 | $33,988,000 | +29.2% | 2,234,528 | -8.4% | 0.01% | +40.0% |
| Q3 2014 | $26,297,000 | -22.1% | 2,438,275 | +10.2% | 0.01% | -28.6% |
| Q2 2014 | $33,775,000 | -23.2% | 2,211,763 | -9.0% | 0.01% | -33.3% |
| Q1 2014 | $43,965,000 | +277.2% | 2,431,670 | +189.8% | 0.02% | +320.0% |
| Q4 2013 | $11,655,000 | +10.3% | 839,134 | -16.7% | 0.01% | -16.7% |
| Q3 2013 | $10,565,000 | +15.5% | 1,007,065 | -14.0% | 0.01% | 0.0% |
| Q2 2013 | $9,148,000 | – | 1,171,354 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |